Personalizing Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer

Jennifer B. Valerin, MD, PhD, discusses strategies for chemotherapy selection in PDAC with targeted therapies poised to enter the treatment paradigm.

Deirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.

Dallas Gallagher, DNP, FNP-C, AOCNP, discusses individualized chemotherapy selection and the importance of a "person-first" approach to pancreatic cancer care.

Dallas Gallagher, DNP, FNP-C, AOCNP, discusses the importance of a patient-focused approach when managing the emotional weight of a pancreatic cancer diagnosis.

Rachna T. Shroff, MD, MS, FASCO, discusses how this “sea change” has coincided with evolving considerations for frontline selection in pancreatic cancer.

Rachna T. Shroff, MD, MS, FASCO, discusses how bringing a diversity of perspectives to clinical trial design has moved the needle in pancreatic cancer.

Rachna T. Shroff, MD, MS, FASCO, and Kristen Spencer, DO, discuss factors weighed when navigating first-line chemotherapy selection in pancreatic cancer.

Deirdre J. Cohen, MD, MS, discusses key considerations when navigating first-line chemotherapy selection in metastatic pancreatic cancer.

Kristen Spencer, DO, discusses first-line regimen selection in metastatic pancreatic adenocarcinoma.

Kristen Spencer, DO, discusses how patient goals are shaping first-line treatment selection for metastatic pancreatic cancer.